Respiratory medicine
-
Respiratory medicine · Jun 2011
Randomized Controlled TrialProfiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
Indacaterol is a novel, inhaled, ultra-long-acting β(2)-agonist bronchodilator for maintenance use in patients with COPD. The aim of this paper is to assess the effect of indacaterol on dyspnoea and health status, using pooled study data to evaluate the relative efficacy of indacaterol and existing bronchodilators. ⋯ Indacaterol provided clinically important improvements in dyspnoea and health status that were at least as good as and often better than those observed with existing bronchodilator treatments for COPD.